Hypertension, Vol 7, 105-112, Copyright © 1985 by American Heart Association
The Hypertension Detection and Follow-up Program followed 10,940
hypertensive adults for 5 years. Participants were monitored with
electrocardiograms (ECGs) and chest x-ray films. Changes in ECG and
cardiothoracic ratio were compared between stepped car and the referred
care groups. In those with tall R wave by ECG at baseline, who survived the
5-year follow-up, incidence of left ventricular hypertrophy (LVH) by ECG
criteria was 4.1% in the stepped care group and 8.6% in the referred care
group (p less than 0.01). In those participants with ECG evidence of tall R
wave or LVH at baseline, the rate of regression toward normal was 54.3% in
the stepped care group and 42.9% in the referred care group (p less than
0.01). Reversal of enlarged cardiac silhouette on chest x-ray film
(cardiothoracic ratio greater than or equal to 0.5) occurred in 47% of the
stepped care group and in 38% of the referred care group (p less than
0.01). These results indicate that the use of systematic antihypertensive
therapy to achieve goal blood pressure reduces the incidence of LVH
enlarged cardiac silhouette in adults with hypertension. In addition, it
was found that antihypertensive treatment tends to reverse previous LVH or
high cardiothoracic ratios toward a normal ECG and chest x-ray film pattern
among hypertensive subjects. These findings are of particular importance
because these indices are predictors of poor prognosis among untreated
patients with hypertension.
ARTICLES
Five-year findings of the Hypertension Detection and Follow-up Program. Prevention and reversal of left ventricular hypertrophy with antihypertensive drug therapy. Hypertension Detection and Follow-up Program Cooperative Group
This article has been cited by other articles:
 |
|
 |
|
  P. Ruggenenti, I. Iliev, G. M. Costa, A. Parvanova, A. Perna, G. A. Giuliano, N. Motterlini, B. Ene-Iordache, G. Remuzzi, and the BENEDICT Study Group Preventing Left Ventricular Hypertrophy by ACE Inhibition in Hypertensive Patients With Type 2 Diabetes: A prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Diabetes Care, August 1, 2008; 31(8): 1629 - 1634. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Okin, E. Gerdts, S. E. Kjeldsen, S. Julius, J. M. Edelman, B. Dahlof, R. B. Devereux, and for the Losartan Intervention for Endpoint Reducti Gender Differences in Regression of Electrocardiographic Left Ventricular Hypertrophy During Antihypertensive Therapy Hypertension, July 1, 2008; 52(1): 100 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Okin, R. B. Devereux, E. Gerdts, S. M. Snapinn, K. E. Harris, S. Jern, S. E. Kjeldsen, S. Julius, J. M. Edelman, L. H. Lindholm, et al. Impact of Diabetes Mellitus on Regression of Electrocardiographic Left Ventricular Hypertrophy and the Prediction of Outcome During Antihypertensive Therapy: The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study Circulation, March 28, 2006; 113(12): 1588 - 1596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Okin, R. B. Devereux, S. Jern, S. E. Kjeldsen, S. Julius, M. S. Nieminen, S. Snapinn, K. E. Harris, P. Aurup, J. M. Edelman, et al. Regression of Electrocardiographic Left Ventricular Hypertrophy During Antihypertensive Treatment and the Prediction of Major Cardiovascular Events JAMA, November 17, 2004; 292(19): 2343 - 2349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. B. Devereux, K. Wachtell, E. Gerdts, K. Boman, M. S. Nieminen, V. Papademetriou, J. Rokkedal, K. Harris, P. Aurup, and B. Dahlof Prognostic Significance of Left Ventricular Mass Change During Treatment of Hypertension JAMA, November 17, 2004; 292(19): 2350 - 2356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. B. J. Mancini, B. Dahlof, and J. Diez Surrogate Markers for Cardiovascular Disease: Structural Markers Circulation, June 29, 2004; 109(25_suppl_1): IV-22 - IV-30. [Full Text] [PDF]
|
|
|
|
|
|
P. M. Okin, R. B. Devereux, S. Jern, S. E. Kjeldsen, S. Julius, M. S. Nieminen, S. Snapinn, K. E. Harris, P. Aurup, J. M. Edelman, et al. Regression of Electrocardiographic Left Ventricular Hypertrophy by Losartan Versus Atenolol: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study Circulation, August 12, 2003; 108(6): 684 - 690. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Penn, M.-Z. Cui, A. L. Winokur, J. Bethea, T. A. Hamilton, P. E. DiCorleto, and G. M. Chisolm Smooth muscle cell surface tissue factor pathway activation by oxidized low-density lipoprotein requires cellular lipid peroxidation Blood, November 1, 2000; 96(9): 3056 - 3063. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-C. Chai, D. G. Binion, and G. M. Chisolm Relationship of molecular structure to the mechanism of lysophospholipid-induced smooth muscle cell proliferation Am J Physiol Heart Circ Physiol, October 1, 2000; 279(4): H1830 - H1838. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-Z. Cui, M. S. Penn, and G. M. Chisolm Native and Oxidized Low Density Lipoprotein Induction of Tissue Factor Gene Expression in Smooth Muscle Cells Is Mediated by Both Egr-1 and Sp1 J. Biol. Chem., November 12, 1999; 274(46): 32795 - 32802. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mosterd, R. B. D'Agostino, H. Silbershatz, P. A. Sytkowski, W. B. Kannel, D. E. Grobbee, and D. Levy Trends in the Prevalence of Hypertension, Antihypertensive Therapy, and Left Ventricular Hypertrophy from 1950 to 1989 N. Engl. J. Med., April 22, 1999; 340(16): 1221 - 1227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Mayet, N. Chapman, C. K.-C. Li, M. Shahi, N. R. Poulter, P. S. Sever, R. A. Foale, and S. A.McG. Thom Ethnic Differences in the Hypertensive Heart and 24-Hour Blood Pressure Profile Hypertension, May 1, 1998; 31(5): 1190 - 1194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Kronig, D. B. Pittrow, W. Kirch, D. Welzel, and G. Weidinger Different Concepts in First-Line Treatment of Essential Hypertension: Comparison of a Low-Dose Reserpine-Thiazide Combination With Nitrendipine Monotherapy Hypertension, February 1, 1997; 29(2): 651 - 658. [Abstract] [Full Text]
|
|
|
|
|
|
J. D. Neaton, R. H. Grimm Jr, R. J. Prineas, J. Stamler, G. A. Grandits, P. J. Elmer, J. A. Cutler, J. M. Flack, J. A. Schoenberger, R. McDonald, et al. Treatment of Mild Hypertension Study: Final Results JAMA, August 11, 1993; 270(6): 713 - 724. [Abstract] [PDF]
|
|
|
|
 |
|
 B. R. Davis, M. D. Blaufox, A. Oberman, S. Wassertheil-Smoller, N. Zimbaldi, J. A. Cutler, K. Kirchner, and H. G. Langford Reduction in Long-term Antihypertensive Medication Requirements: Effects of Weight Reduction by Dietary Intervention in Overweight Persons With Mild Hypertension Arch Intern Med, August 9, 1993; 153(15): 1773 - 1782. [Abstract] [PDF]
|
|
|
|
|
|
F. A. Lederle, W. B. Applegate, and R. H. Grimm Jr Reserpine and the Medical Marketplace Arch Intern Med, March 22, 1993; 153(6): 705 - 706. [Abstract] [PDF]
|
|
|
|
|
|
J. Stamler, R. Stamler, and J. D. Neaton Blood Pressure, Systolic and Diastolic, and Cardiovascular Risks: US Population Data Arch Intern Med, March 8, 1993; 153(5): 598 - 615. [Abstract] [PDF]
|
|
|
|
|
|
D. K. Lee, P. R. Marantz, R. B. Devereux, P. Kligfield, and M. H. Alderman Left Ventricular Hypertrophy in Black and White Hypertensives: Standard Electrocardiographic Criteria Overestimate Racial Differences in Prevalence JAMA, June 24, 1992; 267(24): 3294 - 3299. [Abstract] [PDF]
|
|
|
|
|
|
R. Stamler, R. H. Grimm Jr, A. R. Dyer, J. V. Talano, R. Prineas, R. Crow, R. Berman, F. C. Gosch, P. Elmer, and J. Stamler Cardiac Status After Four Years in a Trial on Nutritional Therapy for High Blood Pressure Arch Intern Med, March 1, 1989; 149(3): 661 - 665. [Abstract] [PDF]
|
|
|
|
|
|
Hypertension Detection and Follow-up Program Coope, N. Shulman, E. Tuttle Jr, G. Entwisle, A. Apostolides, A. Oberman, H. W. Schnaper, E. H. Kass, J. O. Taylor, B. F. Polk, et al. Persistence of Reduction in Blood Pressure and Mortality of Participants in the Hypertension Detection and Follow-up Program JAMA, April 8, 1988; 259(14): 2113 - 2122. [Abstract] [PDF]
|
|